AgingResearch.NewsJoin free

Atorvastatin + resveratrol

Atorvastatin + resveratrol has been studied in 3 papers since 2020: none in people yet, 3 in animals. The research so far is in animals. The newest paper, Mar 1, 2025: “Resveratrol Relieves Hepatic Steatosis and Enhances the Effects of Atorvastatin in a Mouse Model of NAFLD by Regulating the Renin-Angiotensin System, Oxidative Stress, and Inflammation”.

Intervention

3 papers study it1 more mentions it9 findingsUpdated

PubChemPubChemChEBIChEBI

See all 4

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

  • 3 independent labs in 2 countries
  • Funders: Aerostatic Science Foundation and 1 more
  • Animals3

What did studies of atorvastatin + resveratrol find?

8

Studies of atorvastatin + resveratrol measured 8 outcomes; the most studied are metabolic dysfunction-associated steatotic liver disease (2 studies), blood glucose (1) and hepatic steatosis (1).

Metabolic dysfunction-associated steatotic liver disease

downin mice2

2 studies

  1. Atorvastatin + resveratrol decreases metabolic dysfunction-associated steatotic liver disease in high-fat diet-induced NAFLD.

    “ameliorative effects of AT increased considerably when it was administered in combination with RSV”

    Animalsin high-fat diet-induced NAFLDoral gavage20 mg/kg and 100 mg/kg/day4 weeksmales

    Resveratrol Relieves Hepatic Steatosis and Enhances the Effects of Atorvastatin in a Mouse Model of NAFLD by Regulating the Renin-Angiotensin System, Oxidative Stress, and Inflammation

    Food science & nutrition

  2. Atorvastatin + resveratrol decreases metabolic dysfunction-associated steatotic liver disease in high-fat diet-fed mice.

    “resveratrol and atorvastatin combination therapy can improve nonalcoholic fatty liver disease”

    Animalsin high-fat diet-fed mice

    Therapeutic Potential of Resveratrol and Atorvastatin Following High-Fat Diet Uptake-Induced Nonalcoholic Fatty Liver Disease by Targeting Genes Involved in Cholesterol Metabolism and miR33

    DNA and cell biology

More on Metabolic dysfunction-associated steatotic liver disease

Blood glucose

downin mice1

1 study

  1. Atorvastatin + resveratrol decreases blood glucose in mice with fatty liver.

    “this effect was correlated with decreased blood glucose levels, triglyceride, cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol blood levels”

    Animalsin mice with fatty liver

    Therapeutic Potential of Resveratrol and Atorvastatin Following High-Fat Diet Uptake-Induced Nonalcoholic Fatty Liver Disease by Targeting Genes Involved in Cholesterol Metabolism and miR33

    DNA and cell biology

More on Blood glucose

Hepatic steatosis

downin mice1

1 study

  1. Atorvastatin + resveratrol decreases hepatic steatosis in mice with fatty liver.

    “Resveratrol and atorvastatin reduced fat accumulation in the liver of mice with fatty liver”

    Animalsin mice with fatty liverliver

    Therapeutic Potential of Resveratrol and Atorvastatin Following High-Fat Diet Uptake-Induced Nonalcoholic Fatty Liver Disease by Targeting Genes Involved in Cholesterol Metabolism and miR33

    DNA and cell biology

BMSC cell migration

upin O. cuniculus cells1

1 study

  1. Atorvastatin + resveratrol improves BMSC cell migration in O. cuniculus cells (compared with monotherapy).

    “combined treatment further protected BMSCs against rapamycin-induced apoptosis and improved cell migration”

    Cellscompared with monotherapy

    Effect of resveratrol combined with atorvastatin on re-endothelialization after drug-eluting stents implantation and the underlying mechanism

    Life sciences

PI3K/Akt/eNOS signaling

upin O. cuniculus cells1

1 study

  1. Atorvastatin + resveratrol activates PI3K/Akt/eNOS signaling in BMSCs, compared with monotherapy.

    “Combined medication significantly upregulated Akt, p-Akt, eNOS, p-eNOS, and CXCR4 expression in BMSCs compared with the effects of monotherapy”

    Cellsin BMSCs, compared with monotherapy

    Effect of resveratrol combined with atorvastatin on re-endothelialization after drug-eluting stents implantation and the underlying mechanism

    Life sciences

Apoptosis

downin O. cuniculus cells1

1 study

  1. Atorvastatin + resveratrol decreases apoptosis in O. cuniculus cells (rapamycin-induced apoptosis in BMSCs, compared with monotherapy).

    “combined treatment further protected BMSCs against rapamycin-induced apoptosis”

    Cellsrapamycin-induced apoptosis in BMSCs, compared with monotherapy

    Effect of resveratrol combined with atorvastatin on re-endothelialization after drug-eluting stents implantation and the underlying mechanism

    Life sciences

More on Apoptosis

Neointimal formation

upin O. cuniculus1

1 study

  1. Atorvastatin + resveratrol increases neointimal formation in O. cuniculus after drug-eluting stent implantation, compared with monotherapy.

    “the neointimal area and mean neointimal thickness were greater in the combined medication group”

    Animalsafter drug-eluting stent implantation, compared with monotherapyabdominal aorta

    Effect of resveratrol combined with atorvastatin on re-endothelialization after drug-eluting stents implantation and the underlying mechanism

    Life sciences

Re-endothelialization

upin O. cuniculus1

1 study

  1. Atorvastatin + resveratrol improves re-endothelialization in O. cuniculus after drug-eluting stent implantation, compared with monotherapy.

    “the combined medication group, which also exhibited improved re-endothelialization”

    Animalsafter drug-eluting stent implantation, compared with monotherapyabdominal aorta

    Effect of resveratrol combined with atorvastatin on re-endothelialization after drug-eluting stents implantation and the underlying mechanism

    Life sciences

Latest

Related